港股三胎概念股集體上漲 錦欣生殖(1951.HK)漲超11%領漲
格隆匯7月28日丨港A兩地三胎概念股今日集體上漲。港股市場中,昨日獲創始人、董事長及首席執行官集體增持150萬股的錦欣生殖今日大漲超11%領漲板塊,中國飛鶴漲6%,貝康醫療漲4%,寶寶樹集團和H&H國際控股漲超3%。國務院總理李克強在全國優化生育政策電視電話會議上強調:要減輕羣眾生育、養育、教育負擔,實施好三孩生育政策;國務院副總理孫春蘭指出,研究推動將3歲以下嬰幼兒照護費用納入個人所得税專項附加扣除,擴大普惠性學前教育資源供給,推進義務教育優質均衡發展和城鄉一體化,研究實施差異化租賃和購房優惠政策,降低生育、養育、教育成本。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.